Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK

Clinical Infectious Diseases

Volumn 53, Issue 8, 2011, Pages 807-816

  Rockstroh, Jürgen K ^a   Lennox, Jeffrey L ^b   Dejesus, Edwin ^c   Saag, Michael S ^d   Lazzarin, Adriano ^e   Wan, Hong ^f   Walker, Monica L ^f   Xu, Xia ^f   Zhao, Jing ^f   Teppler, Hedy ^f   Dinubile, Mark J ^f   Rodgers, Anthony J ^f   Nguyen, Bach Yen ^f   Leavitt, Randi ^f   Sklar, Peter ^f  

^a UNIVERSITY OF BONN   (Germany)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ORLANDO IMMUNOLOGY CENTER   (United States)

^d and Clinical Center   (United States)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RALTEGRAVIR; TENOFOVIR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ADVERSE OUTCOME; ARTICLE; BODY FAT; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CONVENIENCE SAMPLE; DEMOGRAPHY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS RESISTANCE;

ABSORPTIOMETRY, PHOTON; ADENINE; ADOLESCENT; ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; ORGANOPHOSPHONATES; PYRROLIDINONES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 80052905594     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir510     Document Type: Article

References (10)

1. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C. Sustained antiretroviral efficacy of raltegravir as part of combination antiretroviral therapy in treatment-naive HIV-1 infected patients: 96-week data. J Acquir Immune Defic Syndr 2008; 52:350-6.
2. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-54.
3. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl JMed 2008; 359:355-65.
4. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravirbased versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796-806.
5. Lennox JL, DeJesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010; 55:39-48.
6. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213-26. (Pubitemid 15055349)
7. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369:1261-9. (Pubitemid 46553846)
8. Department of Health and Human Services Panel-Office of AIDS Research Advisory Council. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents (2011). Available at: http://www.aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 4 May 2011.
9. Murphy RL, da Silva BA, Hicks CB, et al. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 2008; 9:1-10. (Pubitemid 351214236)
10. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebomatched, multicenter trial of abacavir/lamivudine or tenofovir/ emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009; 23:1547-56.